Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 13/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478399 | 0.81 | PTK2 (0.63) | MAPK8PTK2MAPK10NPC1RAB9A | |
| SCHEMBL163856 | 0.78 | MAPK8 (0.45) | MAPK8MAPK10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL163466 | 0.78 | JAK2 (0.54) | — | |
| SCHEMBL159515 | 0.75 | AGTR1 (0.50) | MAPK8MAPK10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL167175 | 0.75 | GRIK1 (0.44) | MAPK8MAPK10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18080772 | 0.74 | PTK2 (0.66) | MAPK8PTK2MAPK10NPC1RAB9A | |
| SCHEMBL160679 | 0.73 | KCNN4 (0.40) | MAPK10 | |
| SCHEMBL1680689 | 0.72 | PTK2 (0.73) | MAPK8PTK2MAPK10NPC1TP53 | |
| SCHEMBL163352 | 0.71 | KCNMA1 (0.45) | — | |
| SCHEMBL11946878 | 0.71 | PTK2 (0.71) | MAPK8PTK2MAPK10NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2611812-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030894-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | MAPK8 461/4885PTK2 224/4885MAPK10 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.